Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

Tang, W.H. Wilson; Francis, Gary S.; Hoogwerf, Byron J.; Young, James B.

doi:10.1016/s0735-1097(03)00159-1

Cited by 149 publications

(81 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the effect on LV pressure may be caused in part by pioglitazone-induced fluid retention [20]. Despite increased vascular density at the peri-MI by pioglitazone administration, % fibrosis volume was not changed; therefore, this angiogenic effect could not help reduce % fibrosis volume, in the present study.…”

Section: The Effect Of Orally Administrated Pioglitazone In Cardiac Fcontrasting

confidence: 52%

See 1 more Smart Citation

Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function

et al. 2011

View full text Add to dashboard Cite

The efficacy of transplantation of default human marrowderived mesenchymal stem cells (MSCs) was modest. In this study, our challenge was to improve the efficacy of MSC transplantation in vivo by pretreatment of MSCs with pioglitazone. MSCs were cultured with or without medium containing 1 lM of pioglitazone before cardiomyogenic induction. After cardiomyogenic induction in vitro, cardiomyogenic transdifferentiation efficiency (CTE) was calculated by immunocytochemistry using anti-cardiac troponin-I antibody. For the in vivo experiments, myocardial infarction (MI) at the anterior left ventricle was made in nude rats. Two weeks after MI, MSCs pretreated with pioglitazone (p-BM; n 5 30) or without pioglitazone (BM; n 5 17) were injected, and then survived for 2 weeks. We compared left ventricular function by echocardiogram and immunohistochemistry to observe cardiomyogenic transdifferentiation in vivo. Pretreatment with pioglitazone significantly increased the CTE in vitro (1.9% 6 0.2% n 5 47 vs. 39.5% 6 4.7% n 5 13, p < .05). Transplantation of pioglitazone pretreated MSCs significantly improved change in left ventricular % fractional shortening (BM; 24.8% 6 2.1%, vs. p-BM; 5.2% 6 1.5%). Immunohistochemistry revealed significant improvement of cardiomyogenic transdifferentiation in p-BM in vivo (BM; 0% 6 0% n 5 5, vs. p-BM; 0.077% 6 0.041% n 5 5). Transplantation of pioglitazonepretreated MSCs significantly improved cardiac function and can be a promising cardiac stem cell source to expect cardiomyogenesis.

show abstract

Section: The Effect Of Orally Administrated Pioglitazone In Cardiac Fcontrasting

confidence: 52%

“…4B). Orally administrated pioglitazone alone improved LV systolic pressure of CNT groups, whereas it did not improve echocardiographic parameters, suggesting that pioglitazone-induced water retention [20] might have played a role in this LV pressure to some extent.…”

Section: Effect Of Ppar-c-activated Bm-msc Transplantation On Cardiacmentioning

confidence: 83%

Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Indeed, several investigators have reported that thiazolidinediones (TZD), such as pioglitazone, potentially induced the appearance of edema and subsequent CHF in diabetic patients [26,27]. In contrast, Tang et al have most recently shown the lack of direct association between the risk of fluid retention and the baseline degree of severity of CHF by the treatment with TZD in diabetic patients [28]. Therefore, although the precise mechanism(s) is not clear, it is likely that the reduction of the insulin amount by some insulin-sensitizing agents may, at least, be efficient for the decrease of plasma BNP level, since insulin has the potential to induce sodium retention and volume expansion.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

Abstract. This study investigates whether the plasma brain natriuretic peptide (BNP) level is increased by the clinical traits of diabetes, including its complications, and whether these levels are affected by the presence of other combined diseases such as hypertension, hyperlipidemia, and coronary heart disease (CHD) in patients with diabetes. In 223 patients with Type 2 diabetes, the mean value of plasma BNP reached 32.3 ± 4.1 pg/mL. The levels significantly increased with age, hypertension, and CHD but not with the duration of diabetes, HbA1c level, or hyperlipidemia. With regard to the type of therapy, the BNP levels were significantly lower in the combinations of both sulfonylurea and metformin and sulfonylurea and pioglitazone than those in insulin alone. In addition, the BNP levels in the group with diabetic complications, including retinopathy and nephropathy, and macroalbuminuria were significantly elevated in comparison with those without these complications and macroalbuminuria. Interestingly, however, no difference was observed between these groups after removal of the values in patients with CHD. These results have clarified that the plasma BNP levels in diabetic patients could increase only by the progression of macrovascular diseases, such as CHD, but not by the current diabetic control or diabetic microvascular complications.

show abstract

“…A higher risk of heart failure has been reported in some studies (25), whereas others have actually suggested a reduced risk of heart failure in glitazone-treated patients (26). A recent analysis demonstrated reduced mortality in patients with a prior history of heart failure who were treated with glitazones (27).…”

Section: Glitazones: Other Considerationsmentioning

confidence: 98%

Thiazolidinediones

Kendall¹

2006

Diabetes Care

View full text Add to dashboard Cite

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

Cited by 149 publications

References 16 publications

Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function

Pretreatment of Human Mesenchymal Stem Cells with Pioglitazone Improved Efficiency of Cardiomyogenic Transdifferentiation and Cardiac Function

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Thiazolidinediones

Contact Info

Product

Resources

About